Postoperative pancreatic fistula after resection of pancreatic neuroendocrine tumors: Incidence, predictors, and clinical impact.
Abstract
4177 Background: Postoperative pancreatic fistula (POPF) remain a major source of morbidity after pancreatic surgery. Data specific to pancreatic neuroendocrine tumors (pNETs) are limited, although these neoplasms differ biologically and surgically from pancreatic adenocarcinoma, potentially influencing POPF risk and outcomes. This study evaluated the incidence, predictors, and clinical impact of POPF in a well-characterized cohort of patients undergoing resection for pNETs. Methods: All patients who underwent resection for histologically confirmed pNETs between 2010-2019 at a tertiary center were retrospectively analyzed. Clinicopathological parameters and surgical procedures were assessed for association with POPF occurrence and severity according to the International Study Group on Pancreatic Fistula (ISGPF) criteria. Statistical analyses included χ², Fisher’s exact, Spearman correlation tests, and multivariable regression analysis; significance was defined as α = 0.05. Results: Among 106 patients (44% female, mean age 61 (± 13.5) years), 85% received a formal pancreatic resection, 15% an atypical resection. More than half (53%) of pNETs were located in the pancreatic tail. The majority (64%) of tumors were G1, only 4% G3, with 72% of diseases in early stages UICC I or II. 12% of pNETs were functional and exclusively insulinomas. 53 patients (50%) developed a POPF, predominantly Grade B (60%), followed by Grade A (34%) and Grade C (6%). No surgery- or POPF-related mortality was observed. POPFs were most frequent after distal pancreatectomy for tail lesions (60% vs. 23% body vs. 17% head; p = 0.065), and in functional pNETs (77% vs. 46% in non-functional pNETs; p = 0.072). Distant metastases were inversely associated with POPF (M0 54% vs. M1 28%; p = 0.043). A nonsignificant trend toward higher POPF rates was observed after atypical resections (73% vs. 48%; p = 0.095). Higher POPF grade was associated with female sex (p = 0.016), and tumor proliferation index (p = 0.046); female sex remained independently associated with POPF grade in multivariable regression analysis (beta = 0.334, p = 0.044). Patients with POPF exhibited lower long-term mortality during follow-up (8% vs. 29%; p = 0.009) and lower mean preoperative chromogranin A levels (82.8 ng/mL vs. 167.8 ng/mL; p = 0.038). Conclusions: POPF occurred in half of all pNET resections, most commonly of Grade B severity. Tumor location, functionality, and absence of metastases were associated with higher POPF risk, and female sex with higher grade POPF. The association of POPF with lower long-term mortality likely mirrors the favorable tumor biology and localized disease profile of patients selected for curative surgery. This underscores the long-term oncological benefit of surgical resection in pNETs and provides relevant insights for postoperative risk stratification and perioperative management.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (9)
Oliver Overheu
Department of Hematology and Oncology with Palliative Care, St. Josef Hospital, Ruhr University, Bochum, Germany
Philipp Höhn
Department of General and Visceral Surgery, St. Josef Hospital, Ruhr University, Bochum, Germany
Doreen M. Zucha
Institute of Pathology, Ruhr University, Bochum, Germany
Stefanie Hegenberg
Department of Hematology and Oncology with Palliative Care, St. Josef Hospital, Ruhr University, Bochum, Germany
Julia von Tresckow
4Department of Hematology, Oncology and Palliative Care, Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany
Monika Janot-Matuschek
Department of General and Visceral Surgery, St. Josef Hospital, Ruhr University, Bochum, Germany
Andrea Tannapfel
COLOPREDICT Platform and Institute of Pathology, Ruhr-University, Bochum, Germany
Waldemar Uhl
Department of General and Visceral Surgery, St. Josef Hospital, Ruhr University, Bochum, Germany
Anke C. Reinacher-Schick
COLOPREDICT Platform and Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany